PARTNERING WITH BOEHRINGER INGELHEIM

CardioMetabolic Diseases

Our innovation in CardioMetabolic diseases is evidenced through our long history of excellence in research and landmark clinical trials, culminating in our most recent breakthrough treatments in type 2 diabetes and anticoagulation care. We are also committed to discovering and developing the innovations of the future and are searching for differentiated novel products and new therapeutic concepts (compound-related research targets or new pathways/ideas), with a preference for discovery up to IND-ready programs.

Our specific partnering interests offer various opportunities for collaboration with a focus on therapies that address microvascular and macrovascular complications of diabetes and the metabolic syndrome.

Liver diseases
- Non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis

Diabetic retinopathy (DME, DR, nPDR)

Chronic kidney diseases
- Chronic kidney disease from diabetes and other cardiovascular causes, and approaches targeting pathophysiology in the cardio-renal axis, including heart failure, acute kidney injury, renal inflammation and fibrosis

Novel obesity treatments achieving weight loss > 10%

Breakthrough treatments for type 2 diabetes, Pancreas recovery options

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

Working together for better health

For more information please contact our BD&L team:
Dr. Johannes Zanzinger
johannes.zanzinger@boehringer-ingelheim.com

Dr. Monica Cheng
monica.cheng@boehringer-ingelheim.com